Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene

被引：0

作者：

N I Chowdhury

A K Tiwari

R P Souza

C C Zai

S A Shaikh

S Chen

F Liu

J A Lieberman

H Y Meltzer

A K Malhotra

J L Kennedy

D J Müller

机构：

[1] Neurogenetics Section,Department of Neuroscience, Department of Psychiatry

[2] Centre for Addiction and Mental Health,Department of Neuroscience

[3] University of Toronto,Department of Psychiatry

[4] Laboratory of Neurosciences,undefined

[5] Graduate Program in Health Sciences Health Sciences Unit,undefined

[6] University of the Far South Catarinens,undefined

[7] Molecular Neuroscience,undefined

[8] Centre for Addiction and Mental Health,undefined

[9] University of Toronto,undefined

[10] College of Physicians and Surgeons,undefined

[11] Columbia University and the New York State Psychiatric Institute,undefined

[12] Psychiatric Hospital at Vanderbilt University,undefined

[13] Albert Einstein College of Medicine,undefined

[14] The Zucker Hillside Hospital,undefined

来源：

The Pharmacogenomics Journal | 2013年 / 13卷

关键词：

association study; clozapine; electrophoretic mobility-shift assays; MC4R; pharmacogenetics; weight gain;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Antipsychotic-induced weight gain (AIWG) may result in the metabolic syndrome in schizophrenia (SCZ) patients. Downstream variants of the melanocortin-4 receptor (MC4R) gene have been associated with obesity in various populations. Thus, we examined single-nucleotide polymorphisms (SNPs) in the MC4R region for association with AIWG in SCZ patients. Four SNPs (rs2229616, rs17782313, rs11872992 and rs8087522) were genotyped in 224 patients who underwent treatment for SCZ and were evaluated for AIWG for up to 14 weeks. We compared weight change (%) across genotypic groups using analysis of covariance for three SNPs (r2⩽0.8). European-ancestry patients who were rs8087522 A-allele carriers (AG+AA) on clozapine gained significantly more weight than non-carriers (P=0.027, n=69). These observations were marginal after correction for multiple testing. We performed in vitro electrophoretic mobility-shift assay that suggested that the presence of the A-allele may create a transcription factor-binding site. Further investigation is warranted for both these exploratory findings.

引用

页码：272 / 279

页数：7

共 146 条

[1] Meyer JM(2005)The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome Schizophr Res 80 9-18
[2] Nasrallah HA(2006)Genetics of antipsychotic treatment emergent weight gain in schizophrenia Pharmacogenomics 6 863-887
[3] McEvoy JP(2005)Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from III NHANES Schizophr Res 8 19-32
[4] Goff DC(2006)Prevalence of the metabolic syndrome in veterans with schizophrenia J Psychiatr Pract 12 5-10
[5] Davis SM(2009)Schizophrenia and the incidence of cardiovascular morbidity: a population-based longitudinal study in Ontario, Canada Schizophr Res 115 325-332
[6] Chakos M(2010)Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study J Clin Pharm Ther 35 207-211
[7] Müller DJ(2006)Worldwide trends in childhood overweight and obesity Int J Pediatr Obes 1 11-25
[8] Kennedy JL(2009)Melanocortin-4 receptor mutations in obesity Adv Clin Chem 48 95-109
[9] McEvoy JP(2005)Central regulation of energy balance: inputs, outputs and leptin resistance Proc Nutr Soc 64 39-46
[10] Meyer JM(1997)Targeted disruption of the melanocortion-4 receptor results in obesity in mice Cell 88 131-141

← 1 2 3 4 5 6 7 8 9 10 →